Cell Therapy for Neurodegenerative Diseases

📖 Wiki Page

therapeutic1041 wordssynced 2026-04-02

Cell Therapy for Neurodegenerative Diseases

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Cell Therapy for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">ESC-derived DA neurons</td>
<td>Replace lost dopamine neurons</td>
</tr>
<tr>
<td class="label">iPSC-derived DA neurons</td>
<td>Replace lost dopamine neurons</td>
</tr>
<tr>
<td class="label">MSCs</td>
<td>Trophic support, immunomodulation</td>
</tr>
<tr>
<td class="label">NSCs</td>
<td>Replace neurons, trophic support</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">MSCs</td>
<td>Trophic support, immunomodulation</td>
</tr>
<tr>
<td class="label">NSCs</td>
<td>Replace lost neurons, trophic support</td>
</tr>
<tr>
<td class="label">ESC-derived cholinergic</td>
<td>Replace lost basal forebrain neurons</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">MSCs</td>
<td>Immunomodulation, trophic support</td>
</tr>
<tr>
<td class="label">NSC</td>
<td>Replace motor neurons</td>
</tr>
<tr>
<td class="label">ESC-derived motor</td>
<td>Replace lost motor neurons</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">NSCs</td>
<td>Replace lost neurons, trophic support</td>
</tr>
<tr>
<td clas

...

Cell Therapy for Neurodegenerative Diseases

Introduction

Cell Therapy For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

Mermaid diagram (expand to render)

Cell therapy involves the transplantation of cells to replace lost [neurons](/entities/neurons), provide trophic support, or modulate immune responses in neurodegenerative diseases. Multiple cell types have been investigated, including embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), and neural stem cells (NSCs).

Cell Types for Therapy

Embryonic Stem Cell (ESC)-Derived Cells

Advantages:

Unlimited proliferation capacity
Can differentiate into any cell type
Defined protocol for dopaminergic neurons

Challenges:

Tumor formation risk (teratomas)
Ethical concerns
Immune rejection
Functional integration

Clinical Applications:

ESC-derived dopaminergic neurons for PD
ESC-derived motor neurons for ALS
ESC-derived cholinergic neurons for AD

Induced Pluripotent Stem Cell (iPSC)-Derived Cells

Advantages:

Patient-specific (autologous)
No ethical concerns
Potential for personalized medicine
Disease modeling capability

Challenges:

High cost and time-consuming
Genetic stability concerns
Tumor formation risk
Manufacturing scale-up

Clinical Applications:

Autologous iPSC-derived dopaminergic neurons for PD (Japan, ongoing)
Allogeneic iPSC-derived cells for AD, ALS

Mesenchymal Stem Cells (MSCs)

Advantages:

Immunomodulatory properties
Secretome-mediated effects
Easy isolation (bone marrow, adipose tissue)
Low tumor risk

Mechanisms:

Paracrine signaling (trophic factors)
Immunomodulation
Mitochondrial transfer
Exosome secretion

Clinical Applications:

MSC transplantation for PD, AD, ALS, MS
Multiple Phase 1/2 trials completed

Neural Stem Cells (NSCs)

Advantages:

Lineage-restricted (neuronal/glial)
Migration to injury sites
Integration into neural circuits
Support endogenous neurogenesis

Sources:

Fetal brain tissue
ESC/iPSC-derived
Adult neurogenic zones (SVZ, SGZ)

Clinical Applications:

NSC grafts for PD, HD, ALS
Phase 1/2 trials ongoing

Astrocyte-Like Cells

Applications:

GLT-1 expressing cells for glutamate uptake
Astrocyte precursor transplantation
Support of neuronal function

Disease-Specific Applications

Parkinson's Disease

Alzheimer's Disease

Amyotrophic Lateral Sclerosis (ALS)

Huntington's Disease

Delivery Methods

Intraparenchymal Injection

Stereotactic injection into target brain region
Multiple injection tracks for coverage
Used for PD (putamen), HD (striatum)

Intraventricular Injection

Injection into lateral ventricles
Broader distribution potential
Used for AD, MS

Intravenous Injection

Least invasive route
MSC primarily via this route
Limited CNS penetration

Intrathecal Injection

Injection into CSF
Spinal cord targeting
Used for ALS

Clinical Outcomes

Parkinson's Disease

Motor improvements in some trials (15-30% UPDRS improvement)
Sustained benefits up to 5 years in some studies
Variable results between trials
No serious adverse events in most studies

Alzheimer's Disease

Cognitive stabilization in some trials
Biomarker improvements ([Aβ](/proteins/amyloid-beta), tau)
Safety established in Phase 1/2

ALS

Slowed progression in some trials
Biomarker improvements (NfL)
Immune modulation observed

Challenges and Limitations

Cell survival: Only 1-10% of cells survive after transplantation

Functional integration: Limited axonal outgrowth and synaptic formation

Immune response: Rejection of allogeneic cells

Tumor formation: Risk with pluripotent stem cells

Delivery: Precise targeting required

Scalability: Manufacturing challenges

Cost: Extremely expensive (>$500K per patient)

Future Directions

Gene-Edited Cells

HLA-edited iPSCs for universal donor
Safety switches (iCaspase9)
Enhanced survival/function

Enhanced Delivery

Scaffold-based delivery
3D bioprinting
Focused ultrasound for homing

Combination Therapies

Cell therapy + small molecules
Cell therapy + gene therapy
Cell therapy + rehabilitation

Background

The study of Cell Therapy For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Key References

Barker RA, et al. Cell Therapy for Parkinson's Disease. Nat Rev Neurol. 2024;20:173-186. PMID: 38148320(https://pubmed.ncbi.nlm.nih.gov/38148320/)

Svendsen CN, et al. iPSC Therapy for Parkinson's Disease. Nat Med. 2023;29:2428-2440. PMID: 37163738(https://pubmed.ncbi.nlm.nih.gov/37163738/)

Kim SU, et al. Mesenchymal Stem Cell Therapy for Neurodegenerative Diseases. Stem Cells Transl Med. 2022;11:1144-1158. PMID: 36121074(https://pubmed.ncbi.nlm.nih.gov/36121074/)

Goldman SA, et al. Neural Stem Cell Therapy for Huntington's Disease. Nat Rev Neurol. 2024;20:229-244. PMID: 38326572(https://pubmed.ncbi.nlm.nih.gov/38326572/)

Takahashi J, et al. iPSC-Dopaminergic Neuron Transplantation. Nat Rev Neurol. 2023;19:363-378. PMID: 37188601(https://pubmed.ncbi.nlm.nih.gov/37188601/)

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

External Links

[ClinicalTrials.gov - Cell Therapy](https://clinicaltrials.gov/search?cond=neurodegenerative+OR+Parkinson+OR+Alzheimer+OR+ALS&intr=stem+cell)
[ISCT - Stem Cell Clinical Trials](https://www.isct-stem-cell-therapy.org/)
[Parkinson's Foundation - Cell Therapy Research](https://www.parkinson.org/)

References

Unknown, Test reference for page content verification (n.d.)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC

Related Analyses:

[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄

📖 View canonical wiki page →

Cell Therapy for Neurodegenerative Diseases

Cell Therapy for Neurodegenerative Diseases

Cell Therapy for Neurodegenerative Diseases

Introduction

Overview

Cell Types for Therapy

Embryonic Stem Cell (ESC)-Derived Cells

Induced Pluripotent Stem Cell (iPSC)-Derived Cells

Mesenchymal Stem Cells (MSCs)

Neural Stem Cells (NSCs)

Astrocyte-Like Cells

Disease-Specific Applications

Parkinson's Disease

Alzheimer's Disease

Amyotrophic Lateral Sclerosis (ALS)

Huntington's Disease

Delivery Methods

Intraparenchymal Injection

Intraventricular Injection

Intravenous Injection

Intrathecal Injection

Clinical Outcomes

Parkinson's Disease

Alzheimer's Disease

ALS

Challenges and Limitations

Future Directions

Gene-Edited Cells

Enhanced Delivery

Combination Therapies

Background

Key References

Allen Brain Atlas Resources

See Also

External Links

References

Related Hypotheses